| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 06/20/2002 | WO2002048110A2 Composition for regulating animal growth, method of manufacture and use thereof |
| 06/20/2002 | WO2002048106A2 Isoindolin-1-one glucokinase activators |
| 06/20/2002 | WO2002047719A2 Survical promoting ncam binding and ncam ligand biding compounds |
| 06/20/2002 | WO2002047716A2 Chronic treatment regimen using glucagon-like insulinotropic peptides |
| 06/20/2002 | WO2002047714A1 Management of the consequences of fetal programming |
| 06/20/2002 | WO2002047712A2 Peptide yy and peptide yy agonists for treatment of metabolic disorders |
| 06/20/2002 | WO2002047711A2 Modulators of activity of g-protein-coupled receptor kinases |
| 06/20/2002 | WO2002047708A2 Selective cox-2 inhibition from edible plant extracts |
| 06/20/2002 | WO2002047701A1 Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| 06/20/2002 | WO2002047699A1 Compositions for preventing or ameliorating multiple risk factor syndromes |
| 06/20/2002 | WO2002047687A1 Urotensin-ii receptor antagonists |
| 06/20/2002 | WO2002047685A2 Nmda receptor agonist pharmaceutical compositions |
| 06/20/2002 | WO2002047683A1 Blood lipid ameliorant composition |
| 06/20/2002 | WO2002047682A1 Blood lipid ameliorant composition |
| 06/20/2002 | WO2002047678A1 Antilipemic agents |
| 06/20/2002 | WO2002047673A2 Methods and compositions to treat conditions associated with neovascularization |
| 06/20/2002 | WO2002047493A2 Health promoting compositions |
| 06/20/2002 | WO2002047456A2 Urotensin-ii receptor antagonists |
| 06/20/2002 | WO2002040019A8 Benzimidazole derivatives |
| 06/20/2002 | WO2002020495A3 Inhibitors of glycogen synthase kinase 3 |
| 06/20/2002 | WO2002020464A3 Benzene tricarboxylic acid amides as insulin receptor activators |
| 06/20/2002 | WO2002016436A3 ANTIBODIES TO HUMAN IL-1$g(b) |
| 06/20/2002 | WO2001089570A3 Combination of growth hormone secretagogues and antidepressants |
| 06/20/2002 | WO2001085942A3 Cytoskeleton-associated proteins |
| 06/20/2002 | WO2001083524A3 Rna metabolism proteins |
| 06/20/2002 | WO2001074904A3 G-protein coupled receptors and nucleic acids encoding same |
| 06/20/2002 | WO2001068698A3 Non-selective cation channel |
| 06/20/2002 | WO2001052860A3 Method and composition for modulating an immune response |
| 06/20/2002 | WO2001047528A3 Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes |
| 06/20/2002 | WO2001030328A3 Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions |
| 06/20/2002 | WO2001003688A3 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 06/20/2002 | WO2000077233A9 Complement-resistant non-mammalian dna viruses and uses thereof |
| 06/20/2002 | US20020077360 Administering to a mammal a retinoid campound which binds specifically or selectively to a RAR alpha retinoid receptors in preference over RAR beta and RAR Gamma retinoid receptors, for therapy and prophylaxisof disease or condition |
| 06/20/2002 | US20020077340 Pyridone inhibitors of fatty acid binding protein and method |
| 06/20/2002 | US20020077337 Chemical compounds |
| 06/20/2002 | US20020077329 EP4 receptor inhibitors to treat rheumatoid arthritis |
| 06/20/2002 | US20020077324 Novel polyhydroxypyrazine derivatives, their preparation and the pharmaceutical compostions which comprise them |
| 06/20/2002 | US20020077321 For therapy of tumor metastasis, solid tumor growth (neoplasia), osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, osteopenia, angiogenesis, including tumor angiogenesis and lymphangiogenesis |
| 06/20/2002 | US20020077319 Combination of GABA agonists and aldose reductase inhibitors |
| 06/20/2002 | US20020077318 Substituted azepino[4,5b] indoline derivatives |
| 06/20/2002 | US20020077316 For therapy and prophylaxis of cardiovascular disease, dyslipidemia; dyslipoproteinemia; disorder of glucose metabolism; Alzheimer's Disease; Syndrome X; peroxisome proliferator activated receptor-associated disorder |
| 06/20/2002 | US20020077309 For diagnosis, prognosis, evaluation of therapies and treatment of pancreatic disorders |
| 06/20/2002 | US20020076796 2786, a novel human aminopeptidase |
| 06/20/2002 | US20020076755 G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same |
| 06/20/2002 | US20020076705 Nucleotide sequences which code preferential polypeptide; for use in the detection, treatment, and prevention of alzheimer's, parkinson's, huntington's, Tourette Syndrome, meningitis, encephalitis, congenital disorders and brain |
| 06/20/2002 | US20020076456 Compositions and methods of use for extracts of magnoliaceae plants |
| 06/20/2002 | US20020076447 Suspension or particle-solvent mixture system of zinc-containing calcium phosphate microparticle, and therapeutic agent for treating zinc deficiency |
| 06/20/2002 | US20020076432 Encapsulated long chain alcohols |
| 06/20/2002 | US20020076399 Treatment of immune diseases |
| 06/20/2002 | US20020076395 Modified adipose tissue and related implants and methods |
| 06/20/2002 | DE10060809A1 Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker Substituted anthranilic acids, their use as a medicament or diagnostic, and she containing drug, as well as a pharmaceutical combination preparation with a sodium / hydrogen exchange (NHE) blockers |
| 06/20/2002 | DE10060292A1 Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament Use of substituted benzimidazoles for the manufacture of a medicament for the treatment of diseases which can be influenced by inhibiting the Na + / H + exchanger and containing medicament |
| 06/20/2002 | CA2431800A1 Peptide yy and peptide yy agonists for treatment of metabolic disorders |
| 06/20/2002 | CA2431663A1 Cobalt-porphyrin complexes and use thereof as an anti-obesity agent |
| 06/20/2002 | CA2431406A1 Quinazolinone derivatives |
| 06/20/2002 | CA2431250A1 Composition for regulating animal growth, method of manufacture and use thereof |
| 06/20/2002 | CA2431173A1 Chronic treatment regimen using glucagon-like insulinotropic peptides |
| 06/20/2002 | CA2431172A1 Nmda receptor antagonist pharmaceutical compositions |
| 06/20/2002 | CA2430992A1 Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists |
| 06/20/2002 | CA2430764A1 Blood lipid ameliorant composition |
| 06/20/2002 | CA2430760A1 Antilipemic agents |
| 06/20/2002 | CA2429839A1 Compositions for preventing or ameliorating multiple risk factor syndromes |
| 06/20/2002 | CA2428216A1 Secreted proteins |
| 06/20/2002 | CA2427271A1 Inflammatory markers for detection and prevention of diabetes mellitus |
| 06/20/2002 | CA2365494A1 Lawsonia intracellularis vaccine |
| 06/19/2002 | EP1215207A2 Salts of isoleucyl-thiazolidine and -pyrrolidine and their use as dipeptidylpeptidase inhibitors |
| 06/19/2002 | EP1215203A1 Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient |
| 06/19/2002 | EP1214936A2 Use of thiazolidin- or pyrrolidin-derivatives of aminoacids as antihyperglycemic agents |
| 06/19/2002 | EP1214593A2 Screening for compounds modulating mitochondrial proton leak |
| 06/19/2002 | EP1214443A1 Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells |
| 06/19/2002 | EP1214440A2 Sequence-specific dna recombination in eukaryotic cells |
| 06/19/2002 | EP1214422A1 Phosphatases which activate map kinase pathways |
| 06/19/2002 | EP1214409A1 Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity |
| 06/19/2002 | EP1214404A1 Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| 06/19/2002 | EP1214350A1 Peptides for combating the autoantibodies that are responsible for dilatative cardiomyopathy (dcm) |
| 06/19/2002 | EP1214342A1 Steroid hormone receptor polynucleotides, polypeptides, and antibodies |
| 06/19/2002 | EP1214337A2 Proteins associated with cell differentiation |
| 06/19/2002 | EP1214335A1 Gamma-carboxyglutamate containing conopeptides |
| 06/19/2002 | EP1214325A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| 06/19/2002 | EP1214324A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| 06/19/2002 | EP1214313A2 Heteroaryloxy propanolamines, preparation method and pharmaceutical compositions containing same |
| 06/19/2002 | EP1214305A1 Benzylidene-thiazolidinediones and analogues and their use in the treatment of inflammation |
| 06/19/2002 | EP1214304A1 Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes |
| 06/19/2002 | EP1214303A1 Heterocyclic compounds and methods of use thereof |
| 06/19/2002 | EP1214302A1 Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors |
| 06/19/2002 | EP1214301A1 Hypoglycemic n,n-arylsulfonylglycine compounds |
| 06/19/2002 | EP1214296A1 Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity |
| 06/19/2002 | EP1214295A2 Hydroxyacetamidobenzenesulphonamide derivatives |
| 06/19/2002 | EP1214293A1 Non-peptidic cyclophilin binding compounds and their use |
| 06/19/2002 | EP1214292A1 Tyrosine derivatives |
| 06/19/2002 | EP1214291A1 Biphenyl derivatives used as nhe-3 inhibitors |
| 06/19/2002 | EP1214287A1 Amides as inhibitors for pyruvate dehydrogenase |
| 06/19/2002 | EP1214093A1 Method for producing a tablet made of isomaltulose, isomalt or isolmalt variants |
| 06/19/2002 | EP1214091A1 Therapies for chronic renal failure using one or more integrin antagonists |
| 06/19/2002 | EP1214089A1 Therapeutic uses of m3 polypeptide |
| 06/19/2002 | EP1214084A2 An anti-oxidant preparation based on plant extracts for the treatment of circulation and adiposity problems |
| 06/19/2002 | EP1214070A2 Polyhydroxylated benzene-containing compounds |
| 06/19/2002 | EP1214048A1 Use of conjugated linoleic acid (cla) for the topical treatment of cellulite |
| 06/19/2002 | EP1213972A1 Composition comprising an alpha-amylase inhibitor and at least one physiologically acceptable compound capable of reducing intestinal absorption of "fast sugars" |
| 06/19/2002 | EP1213971A1 Improving condition of elderly pets |